EndoSure Announces a New Strategic Alliance with Maipl Therapeutics, Inc.
Jonathan Eilberg • May 20, 2025

MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY

SCARSDALE, N.Y., May 20, 2025 /PRNewswire/ -- Maipl Therapeutics, Inc. ("Maipl"), a biopharmaceutical company focused on first‑in‑class, non‑hormonal therapies for women's health, today announced a strategic alliance with Endosure, Inc., the developer of the ENDOSURE TEST—the only Tier-1 non‑invasive, 30-minute and highly accurate diagnostic with rapid results capable of diagnosing or excluding the presence of endometriosis in any anatomical location. The collaboration will leverage the ENDOSURE TEST to expedite Maipl's clinical studies of MA-4604, a potent and selective antagonist of the Prostaglandin‑F2α receptor (FP), with the goals of accelerating patient identification, enrollment and pharmacodynamic assessment.

Click to Read the Full Press Release >>


Endometriosis patient using the EndoSure Test

Diagnostic Testing for Endometriosis: Finally, a Tier-1 Diagnostic Test

By Mark Noar • May 21, 2025
Patients no longer need to wait nearly a decade for a diagnosis. Read how the ENDOSURE TEST enables providers to detect endometriosis without surgery.
Endometriosis Symptoms Explained

Understanding Endometriosis: A Detailed Look at Common Symptoms

By Jonathan Eilberg • May 9, 2025
EndoSure reveals some of the most common endometriosis symptoms in detail, so you can begin to piece together whether you may or may not have this disease.